seize; in practice, an individual who has two or more unprovoked seizures is epileptic and will usually continue to have seizures unless successfully treated. Epilepsy affects 1% of people worldwide, in an estimated 40% of whom it is genetically determined (3) . Other causes of epilepsy include trauma, stroke and tumors.
In wakefulness, brain activity is in a state of apparent chaos. Like busy workers in a busy city, every neuron is acting and reacting, which in turn generating consciousness and the other characteristics and abilities of the mind. During sleep, specialized neurons in the thalamus with profuse connections to the entire brain ( Fig. 2) gradually disrupt the individual activities of cortical neurons and entrain them all into monotonous rhythmic synchronized discharges (4) . Therefore, synchronized activity of large numbers of neurons abolishes their normal 'wakeful' functions.
A seizure also consists of synchronized firing of large numbers of neurons. There are two main types of seizures. In primarily generalized seizures, the thalamocortical circuitry is involved early in the attack and results in synchronized firing of neurons brain-wide, unconsciousness and often violent rhythmic shaking of body parts. In focal-onset seizures, the synchronized activity is restricted to one part of the cortex (e.g. to the arm control area of the right hemisphere, resulting in left-arm shaking) and may or may not subsequently spread to recruit the thalamocortical pathways and result in secondary generalization (5) .
Firing of an action potential by a neuron results from threshold depolarization of its cross-plasma membrane voltage. This voltage is regulated by numerous ion channels that open or close, some in response to synaptic neuromediators and others in response to changes in the voltage itself. It is easy to imagine that genetic mutations in singly or groups of channels will result in altered neuronal excitability, which, in certain situations, will cause recurrent firing and driving of a network of neurons into synchrony and a seizure. It is important to remember that 'increased excitability' is not synonymous with seizure, e.g. the increased excitability could be in inhibitory neurons. The final outcome of seizure due to excitability change depends very much on which neurons in which networks are affected.
This review restricts itself to the genetic causes of epilepsies occurring in previously well individuals with no evident underlying brain disorder before the onset of seizures. The first section addresses the roles of excitatory ion channels (Na and Ca), the second, inhibitory channels (K and Cl), and the third, non-ion channel genes. In all cases, so far the resultant epilepsies are autosomal dominant disorders or sporadic syndromes due to de novo hemizygous mutations (Table 1) .
EXCITATORY ION CHANNEL EPILEPSY GENES

Sodium channel mutations
Nine genes encode a-subunits of voltage-gated Na channels. Four of these are highly expressed in neurons of the central nervous system: SCN1A (Na v 1.1), SCN2A (Na v 1.2), SCN3A (Na v 1.3) and SCN8A (Na v 1.6). The first evidence for a role of this gene family in epilepsy came from positional cloning of the inherited syndrome generalized epilepsy with febrile seizures plus (GEFSþ), a mild disorder with a variable epileptic phenotype including fever-induced seizures. Two families with gene loci mapped to chromosome 2q24 families contained missense mutations in evolutionarily conserved residues of SCN1A, changing amino acid residues within or close to transmembrane segments of the protein (6) . Since then, 13 additional missense mutations of SCN1A have been identified, accounting for 10% of GEFSþ families tested (Fig. 3A) . In functional assays, these missense mutations 
2492
Human Molecular Genetics, 2005, Vol. 14, No. 17
produce subtle changes, such as increased persistent current and alterations in voltage-dependent gating, in biophysical parameters of channel activity (7 -10) . One GEFSþ mutation in the C-terminal cytoplasmic domain of SCN1A reduced interaction with the b1-subunit (11) . In addition to inherited mutations, it is now clear that de novo mutations of SCN1A account for 50% of patients with severe myoclonic epilepsy of infancy (SMEI), a severe, early-onset epilepsy accompanied by intellectual deterioration (12) . Nearly 200 independent mutations have been identified in affected children, and more than 90% of tested cases were sporadic. Approximately half of the SMEI mutations are nonsense mutations resulting in truncation of the channel protein and loss of channel activity (Fig. 3B) . The observation that phenotypic severity is comparable to truncations close to the N-terminus of the protein and those close to the C-terminus indicates that loss of function is the common feature and demonstrates haploinsufficiency for SCN1A (13) . Many missense mutations in SMEI patients also result in loss of function (14) . It now appears that the SCN1A-related epilepsies comprise a spectrum of severity ranging from the mildest cases of GEFSþ characterized by childhood seizures without progression, through a wide range of variable phenotypes, to the devastating loss of function mutations in SMEI.
A small number of mutations have been identified in the closely related channel SCN2A, located 600 kb downstream from SCN1A. One missense mutation of SCN2A was found in a GEFSþ family (15) , and six missense mutations were identified in patients with benign familial neonatal -infantile seizures, a mild syndrome that presents and remits in the first year of life (16, 17) . One truncation mutation of SCN2A was identified in a patient with intractable epilepsy resembling SMEI (16, 17) .
The Na channel b-subunits, b1-b4, are small transmembrane proteins with an extracellular IgG loop (Fig. 3A) . Association with the b-subunit influences a-subunit trafficking, stability and channel gating (18) . Two different mutations in the b1 gene SCN1B have been identified in patients with GEFSþ ( Fig. 3A) (19, 20) . The major effect of the b-subunit mutations seems to delay Na channel inactivation, similar to many of the SCN1A missense mutations in GEFSþ patients.
Calcium channel mutations
Ten genes encode a-subunits of voltage-gated Ca channels. Each a-subunit pairs with b-and a2d-subunits (each of which has four subtypes), as well as a g-subunit (eight subtypes) in certain instances. The magnitude of combinations linking these subunits allows for vast diversity in the regulation of Ca entry.
Several coding single nucleotide polymorphisms (SNPs) have been found in the CACNA1H gene in rare patients with primarily generalized seizures, and not in a large number of controls. The patients included cases of childhood absence epilepsy (CAE) (21 -23), a common pediatric epilepsy with frequent unconscious staring spells without convulsion. CACNA1H encodes an a-subunit that determines the Ca v 3.2 T-type calcium channel, which is critically linked to the synchronizing activity of the thalamus (4, 24) and which is modulated by ethosuximide (25) , the drug of choice for CAE. Furthermore, the various epilepsy-associated CACNA1H SNPs alter properties of the channel in ways predicted to generate seizures (23, 26, 27) . Together, these results suggest that these SNPs are true mutations, explaining a small fraction of CAE. A truncating mutation in CACNB4 was found in a small family segregating juvenile myoclonic epilepsy (JME) (28), a very common epilepsy of adolescence with early morning jerks of the arms and generalized convulsions. The CACNB4 observation has not yet been confirmed in other JME cases. Other CACNB4 mutations, and mutations in CACNA1A, cause episodic ataxia type 2 and hemiplegic migraine. These disorders are not epilepsies, because they do not involve synchronized firings of large numbers of cortical neurons. 
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Nonetheless, many affected members in these families do also suffer bona fide seizures, indicating that these Ca channel genes also drive seizures when their properties are altered (28 -33) .
Mutations in the a4b2 nicotinic acetylcholine receptor
Nicotinic acetylcholine receptors are ligand (acetylcholine)-gated cation (Na and Ca) channels. They are pentamers of two types of subunits (a and b). a4 combined with b2 is the most common arrangement in brain (34) . Six missense mutations causing an autosomal dominant nocturnal frontal lobe-onset epilepsy (ADNFLE) have been identified in a4b2, four in a4 (CHRNA4 ) and two in b2 (CHRNB2 ) (35) . One of the a4 mutations is the first epilepsy-causing mutation discovered (36) . a4b2 occupies a particular neuronal location, and its mutations appear to cause epilepsy through a particularly interesting mechanism (37), which are worth elaborating (Fig. 4) . It is present at the presynaptic side (axonal side) of both glutamatergic and GABAergic synapses. (Glutamate and GABA are the main excitatory and inhibitory neurotransmitters in brain. Glutamate receptors are Ca channels, which take in large amounts of Ca when stimulated. GABA receptors are Cl channels.) (38) The patch of presynaptic membrane occupied by a4b2 at these synapses is itself postsynaptic to a cholinergic synapse. Opening of a4b2 with cholinergic stimulation depends on a strong allosteric effect of extracellular Ca (39) . When a4b2 opens, it adds local depolarization to the wave of depolarization arriving to the axon terminus with the action potential. ADNFLE mutations have in common the property of eliminating the allosteric Ca effect on a4b2 (37, 40) . This has led to the following theory to explain how these mutations cause sleep-induced seizures. Normally, with the recurrent stimulation of cortical neurons by the thalamus during sleep, Ca in glutamatergic synapses is reduced (absorbed by the glutamate receptors) and the Ca effect on a4b2 is diminished. At GABAergic synapses, Ca is not depleted and continues to activate a4b2. In sum, inhibitory GABAergic synapses are active and excitatory synapses are inactive during sleep. With ADNFLE mutations, Ca cannot activate a4b2, inhibition in brain is lost during a time of recurrent synchronizing firing by the thalamus and a seizure is generated (Fig. 4) (37) .
INHIBITORY ION CHANNEL EPILEPSY GENES
Potassium channel mutations
The principal role of K channels is stabilization of the cell membrane potential including termination of intense activity, dampening of repetitive firing and lowering the effectiveness of excitatory inputs onto the cell. Among ion channels, K channel gene diversity is particularly striking, with 24 major classes and more than 80 different subunit genes (41) . To date, three of these genes, KCNQ2 (42,43), KCNQ3 (44) and KCNA1 (45, 46) , have been implicated in epilepsy.
KCNQ2 and KCNQ3 proteins combine in a heteromer to form the M type K current, which slowly activates in the voltage range of action potential initiation, repolarizing the membrane and suppressing repetitive firing (47) . Mutations of KCNQ2 and KCNQ3 result in benign familial neonatal convulsions, where seizures occur essentially only in the first month of life and are inducible by provoked or natural arousal from sleep (48, 49) . Forty-eight mutations have been reported, most in KCNQ2 (50 -54) including three de novo mutations in non-inherited cases (55) (Fig. 3C) .
Mutations in KCNA1 were first identified in families with episodic ataxia type 1 (Fig. 3D) . In two families, missense mutation in KCNA1 was associated with focal-onset epilepsy (45, 46) . KCNA1 is a rapidly activating, delayed-rectifier K channel (K v 1.1) that is primarily involved in the recovery phase of action potentials (41, 56) . Mutations in KCNA1 associated with epilepsy dramatically reduce K currents in vitro (45, 46) , and knockout mice exhibit spontaneous focalonset seizures (57).
Chloride channel mutations: the GABA A receptors
GABA A receptors are ligand (GABA)-gated Cl channels, which mediate fast inhibition. Their molecular structure comprises a heteropentameric protein complex assembled from 17 different classes of subunits (a1-6, b1-4, g1-3, . . .d, e, p and u). Thus far, epilepsy-causing mutations have been identified in GABRG2, GABRA1, and GABRD, encoding, respectively, the a1, g2 and d-subunits (58 -63), and in vitro functional studies have revealed that the majority of these mutations result in a reduction of GABA-activated Cl currents (Fig. 5) (58, 60, 63, 64) .
In GABRG2, two mutations cause GEFSþ (58, 62) and two others result in febrile seizures and CAE (59, 61) . In GABRA1, one mutation segregates with rare JME families (60, 65) , and in GABRD, two missense mutations are associated with GEFSþ (63) . One of these GABRD mutations, E177A, like GABRG2 and GABRA1 mutations, results in decreased amplitude of GABA-evoked currents, the other, R220C, does not. Whether it is a rare neutral variant or is associated with more subtle effects on the GABA A receptor remains to be determined. In the same study, another variant, R220H, was detected in a JME family, but it was also present in the general population with a frequency of 4.2%. Nonetheless, this polymorphism reduced GABA-evoked currents, which is expected to increase neuronal excitability. This and similar functional polymorphisms represent candidates for the modifier gene -dose effects anticipated in common epilepsies with complex inheritance, including JME and CAE.
Chloride channel mutations: the voltage-gated chloride channels
Five epilepsy mutations have been identified in the CLCN2 gene (encoding the ClC-2 voltage-gated chloride channel) (66, 67) , three of which have been subject to functional studies. The M200fsX231 and del74 -117 mutations completely abolish the ClC-2 current. In contrast, the G715E mutation appears to act through a different mechanism. It alters ClC-2 gating, resulting in an outward (reverse) chloride current expected to severely affect membrane potential stability and responses to polarity changes (66) .
Human Molecular
The phenotypic outcomes of the aforementioned mutations were remarkably varied. M200fsX231 was associated primarily with JME, del74 -117 with generalized seizures upon awakening and G715E with juvenile absence epilepsy (a juvenile form of CAE) (66) . These three epilepsies have primarily generalized seizures in common, but each has long been categorized as a separate clinical syndrome (65, 68) . Therefore, the CLCN2 mutations in this study raise the possibility that variations in the same ion channel can underlie major syndrome-defining differences. Alternatively, CLCN2 mutations merely predispose to generalized seizures, and modifier genes, different in each family, account for the phenotypic differences.
It is abundantly evident that epilepsy due to ion channel mutations is characterized by wide clinical and genetic heterogeneity. All the mutations reviewed earlier account for a mere Figure 4 . Model of sleep-related seizures due to mutations in the a4b2 nicotinic acetylcholine receptor (37, 40) . (A) At GABAergic synapses (inhibitory), Ca can no longer contribute to the activation of the acetylcholine receptor cation channel, because of mutation of its allosteric binding site on the channel (red dot). Decreased conduction through this cation channel results in decreased presynaptic amplification of the sleep-related trains of thalamocortical action potentials, and therefore, decreased synaptic transmission. (B) At glutamate synapses (excitatory), because synaptic Ca is quickly depleted into postsynaptic dendrites through glutamate receptors during repeated thalamocortical firing, it does not normally contribute to acetylcholine receptor activation. In sum, GABAergic synapses, but not glutamate synapses, are affected by the mutation during sleep, resulting in decreased inhibitory neurotransmission and seizure.
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Human Molecular Genetics, 2005, Vol. 14, No. 17 fraction of the genetic contribution to epilepsy, and it is likely that many more ion channel mutations, singly or in groups, or mutations in proteins affecting ion channel functions will be found, tweaking the brain towards synchronized firings and seizures. However, epilepsy is also expected to result from miswirings in sections of the neural network, and perhaps some of the mutations discussed in the next section act in this fashion.
NON-ION CHANNEL EPILEPSY GENES
LGI1 Originally identified in glioma studies (69) , the leucine-rich glioma-inactivated (LGI1 ) gene is currently considered not to play any important role in brain tumors (70) . Instead, its mutations result in a focal-onset epilepsy with onset in or near the auditory center in the temporal lobe of the brain, resulting in auditory seizures with or without generalization to convulsion and unconsciousness (71 -76) .
Little is known about the LGI1 protein function (named LGI1 and epitempin). It consists of an N-terminal leucinerich repeat region and a C-terminal EAR (epilepsy-associated repeat) region (77) , and it is a secreted protein (78, 79) . The EAR region is a common feature with the Mass1 gene product mutated in the Frings mouse model of audiogenic epilepsy (77) . Introduction of epilepsy-associated mutations results in unstable protein, suggesting that the mutations act through a loss of function mechanism (79) . Finally, LGI1 appears to play a major role in suppressing the production of MMP1/3 through the phosphatidylinositol 3-kinase/ERK pathway. How LGI1 mutations result in seizure generation remains completely unknown, and why the temporal cortex is affected is equally mysterious. It is possible that LGI1 affects ion channels with particular relevance to auditory cortex or that it influences proper auditory cortex neuronal network establishment.
EFHC1
EFHC1 is yet another gene mutated in some families with JME. Its protein product, EFHC1 or myoclonin 1, localizes in the soma and dendrites of neurons in multiple brain regions. EFHC1 interacts with the R-type voltage-dependent Ca channel (Ca v 2.3) and leads to a specific increase of this current when expressed in tissue culture. Introduction of JME mutations greatly reduces the activating effect of EFHC1 on the channel (80) .
EFHC1 may therefore cause JME through neuronal membrane electrical destabilization, as is the case in JME due to ion channel mutations. However, further studies raise an alternate or additional possibility. EFHC1 is pro-apoptotic, and the apoptosis it induces is reduced by EFHC1 JME mutations. EFHC1-induced apoptosis is also specifically suppressed by a Ca v 2.3 antagonist, suggesting that it is driven by the Ca influx through this channel (80) . During normal brain development, neuronal numbers and processes overshoot and are then trimmed as the final structure is established (81, 82) . The few JME brains that have been studied pathologically (83) , or with detailed magnetic resonance imaging (84) , reveal mildly thickened cerebral cortex and dystopic neurons. It is therefore possible that EFHC1 mutations result in insufficient apoptotic shedding of unnecessary neurons during development and produce an imperfect, overpopulated and epileptogenic, cerebral network (80).
BRD2 and ME2
Finally, highly significant associations have been reported between non-coding SNPs in the BRD2 gene and JME (85) and in the ME2 gene and primarily generalized epilepsies including JME (86) . BRD2 is a putative developmental transcription regulator expressed in brain and may be involved in the JME cortical microdysgenesis as mentioned earlier (85) . ME2 encodes malic enzyme 2, a mitochondrial enzyme involved in the synthesis of GABA, the ubiquitous inhibitory neuromediator (86) .
The difficulty with the intriguing BRD2 and ME2 observations is in finding ways of establishing animal models to confirm the roles of these genes and as models for pathogenetic studies. This difficulty is shared with the increasing number of other common genetic diseases found segregating with SNPs. In most such instances, it is problematical to identify the effect of the SNP on its associated gene and find ways to replicate that effect in a mouse. Furthermore, most of these diseases are complex in inheritance, and one would need to identify and recreate several if not many participating polymorphisms. Perhaps, the solution will come not so much from engineered mice, but through detailed clinical and genetic studies in domesticated animals. A first canine epilepsy gene has already been discovered, albeit in the monogenic Lafora progressive myoclonus epilepsy (87) . Epilepsy in dogs is five to 10 times more common than that in man (88) . If, for example, naturally occurring JME could be characterized in dog, then one could attempt to replicate the genetic associations with BRD2, ME2 and other JME genes in dog families, confirming the associations in a different organism and, at the same time, establishing an animal model. Figure 5 . The A322D GABRA1 mutation appears to reduce GABA A Cl currents through reduced surface expression of the mutated protein. HEK 293 cells were co-transfected with a1-EGFP/b2/g2, a1-A322D-EGFP/b2/g2, or EGFP alone and visualized using laser-scanning microscopy. Membrane specific labeling was performed by adding FM4-64 to the medium used for live confocal imaging. The overlay shows a clear localization in the surface membrane for wild-type, but not for mutant GABA A receptors (95) . EGFP, enhanced green fluorescent protein.
Many more epilepsy genes than the ones reviewed in this article remain to be discovered. Epilepsy mutations affect proteins that regulate action potentials and synaptic function, both of which underlie neuronal communication. They also appear to affect proteins involved in proper cortical network establishment. Identifying epilepsy proteins and understanding their functions are clearly critical to better care for the tens of millions of patients afflicted with seizures (and with the devastating unpredictability of seizures). They are also of great value to the understanding of neuronal network formation and communication, i.e. ultimately, to the understanding of the human brain by the human brain.
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